AstraZeneca plc (AZN) Earns Buy Rating from Bryan, Garnier & Co
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Bryan, Garnier & Co in a report issued on Tuesday.
AZN has been the subject of a number of other research reports. HSBC set a GBX 4,815 ($60.16) price target on AstraZeneca plc and gave the stock a “neutral” rating in a research report on Tuesday, August 2nd. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 4,900 ($61.22) price target (up previously from GBX 4,800 ($59.97)) on shares of AstraZeneca plc in a research report on Monday, August 8th. Beaufort Securities reaffirmed a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, August 10th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.98) price target on AstraZeneca plc and gave the stock a “sell” rating in a research report on Wednesday, August 10th. Finally, Jefferies Group boosted their price target on AstraZeneca plc from GBX 4,800 ($59.97) to GBX 5,050 ($63.09) and gave the stock a “hold” rating in a research report on Thursday, August 4th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of GBX 4,974.56 ($62.15).
AstraZeneca plc (LON:AZN) opened at 4353.00 on Tuesday. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The company’s market cap is GBX 55.07 billion. The firm’s 50-day moving average price is GBX 4,706.25 and its 200-day moving average price is GBX 4,580.34.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.